The tenth anniversary of the European Research Council (ERC) has been marked by a series of events and a video featuring some of Oxford's recipients of ERC funding. In a video to mark the anniversary, a number of Oxford University academics have explained how ERC funding has been vital to their research, including Adrian Hill, Director of the Jenner Institute.
A new call for Medical Research Council (MRC) Confidence in Concept funding has just been launched as part of the Tropical Infectious Disease Consortium (Jenner Institute, London School of Hygiene & Tropical Medicine, Liverpool School of Tropical Medicine, and Public Health England). The MRC are ...
A new partnership has been formed between European and African researchers to develop an AIDS vaccine that can be used to prevent infection with different strains of HIV worldwide. Led by Professor Tomáš Hanke at the Jenner Institute, the Globally Relevant AIDS Vaccine Europe-Africa Trials Partnership (GREAT) will evaluate a new vaccine that triggers the body to produce specialised immune cells called T-cells, which will be trialled at four sites in Kenya, Uganda and Zambia.
University of Oxford/University of Cape Town PhD Exchange Programme: Applications are open for the Newton/RCUK PhD partnership scheme for PhD students within medical sciences. There is an opportunity for 8 University of Oxford DPhil students to visit the University of Cape Town on a 4 month exchange visit, with an equivalent opportunity for University of Cape Town PhD students to visit the University of Oxford. The scheme covers the costs of the exchange visits, a stipend, a contribution to research and bench fees or equivalent and additional partnering activities.
The ‘Vaccinology in Africa’ Master’s level course is now open to applications from students, researchers and professionals resident in East Africa. 40 bursaries are available for this fully funded course which covers the main aspects of human and veterinary vaccinology, the vaccine development process, biomanufacturing, clinical trials, regulatory and ethical issues, highlighting human and veterinary links and synergies. The course is jointly organised by the host institution, MUII-Plus (Makerere University-UVRI Centre of Excellence for Infection & Immunity Research and Training) in Entebbe, Uganda, and the Jenner Institute, University of Oxford.
Scientists have named three relatively little-known diseases they think could cause the next global health emergency. A coalition of governments and charities has committed $460m to speed up vaccine development for MERS (Middle East Respiratory Syndrome), Lassa fever and Nipah virus. At the Jenner Institute, scientists are developing vaccines for all three of the viruses. Their MERS vaccine candidate is currently at the most advanced stage worldwide. It is expected that it will be trialled in humans by the end of the year.
Jenner Institute scientists, Dr Lynda Coughlan and Prof Adrian Hill have been awarded the 2016 British Medical Association HC Roscoe grant for a research project which aims to develop improved vaccines for influenza. Fifteen medical academics and research scientists were awarded a total of ...
UK researchers creating new vaccines for epidemic diseases such as Zika and Ebola are among the winners of £22 million of funding, announced by the Department of Health today. These projects will be the first to benefit from the UK Vaccine Network, a £120 million fund launched last year to support Britain’s world-leading role fighting deadly diseases. The network brings together leading figures from industry, academia and philanthropy, including the Jenner Institute, University of Oxford, the Wellcome Trust, and GlaxoSmithKline (GSK).
In this issue, there is a particular highlight on Outbreak Pathogens. In the past months, Jenner researchers have received major funding to manufacture and clinically develop vaccine candidates against several outbreak pathogens of international concern: Zika, Chikungunya, MERS and Rift Valley Fever. Recently, the Jenner Institute has also initiated research programmes on vaccines against non-communicable diseases such as prostate cancer and psoriasis, and Prof Lucy Dorrell’s group is utilizing the Jenner Institute’s viral vector prime-boost platform to deliver therapeutic vaccine against cervical pre-cancer.
If you have news or events that you would like to be added to this website, please email us details. If possible, please include a picture and links to further information.